

# Steroid Hormone Receptors in Prostate Cancer: A Hard

Cancer Cell

16, 458-462

DOI: [10.1016/j.ccr.2009.11.006](https://doi.org/10.1016/j.ccr.2009.11.006)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 17-22.	0.9	11
3	Exploiting the balance between life and death: Targeted cancer therapy and "oncogenic shock". <i>Biochemical Pharmacology</i> , 2010, 80, 666-673.	2.0	53
4	Translating cancer research into targeted therapeutics. <i>Nature</i> , 2010, 467, 543-549.	13.7	310
5	Androgènes récepteurs et cancer de la prostate : nouvelles thérapies à l'horizon. <i>Bulletin Du Cancer</i> , 2010, 97, 739.	0.6	0
6	Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4319-4324.	3.2	71
7	Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1027-1030.	1.1	9
8	Molecular genetics of prostate cancer: new prospects for old challenges. <i>Genes and Development</i> , 2010, 24, 1967-2000.	2.7	811
9	New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 837-846.	1.9	31
10	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1995-2005.	13.9	3,736
11	Drug resistance in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 12-23.	12.5	286
12	New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 1649-1657.	3.2	177
13	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 206-218.	2.0	25
14	Androgen receptor-driven chromatin looping in prostate cancer. <i>Trends in Endocrinology and Metabolism</i> , 2011, 22, 474-480.	3.1	45
15	What is the pathophysiology of a hormone-resistant prostate tumour?. <i>European Journal of Cancer</i> , 2011, 47, S179-S188.	1.3	22
16	Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2011, 47, S189-S194.	1.3	5
17	Characterisation of human prostate epithelial progenitor differentiation in response to androgens. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, 424-428.	0.3	5
18	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011, 21, 241-247.	0.9	12
19	Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2011, 107, 13-20.	1.3	35

#	ARTICLE	IF	CITATIONS
20	Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. <i>Journal of Pineal Research</i> , 2011, 51, 297-312.	3.4	36
21	Revisiting the concept of cancer stem cells in prostate cancer. <i>Oncogene</i> , 2011, 30, 1261-1271.	2.6	100
22	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2011, 60, 270-278.	0.9	53
23	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011, 19, 573-574.	7.7	15
24	Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. <i>Cancer Cell</i> , 2011, 19, 792-804.	7.7	449
25	Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. <i>Journal of Hematology and Oncology</i> , 2011, 4, 18.	6.9	56
26	Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli. <i>Journal of Cellular Physiology</i> , 2011, 226, 2731-2739.	2.0	13
27	Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone. <i>Clinical Cancer Research</i> , 2011, 17, 5844-5849.	3.2	65
28	Intratumoral <i>De Novo</i> Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors. <i>Cancer Research</i> , 2011, 71, 6503-6513.	0.4	383
29	Urinary Prostate-Specific Antigen is Elevated in Female Patients with Cushing's Syndrome. <i>Laboratory Medicine</i> , 2011, 42, 102-105.	0.8	0
30	Emerging Treatments for Castrate-Resistant Prostate Cancer. <i>Journal of Pharmacy Practice</i> , 2011, 24, 366-373.	0.5	1
31	Identification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer. <i>Cancer Research</i> , 2011, 71, 1978-1988.	0.4	38
32	Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3867-3875.	3.2	53
33	Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer. <i>Oncologist</i> , 2011, 16, 1413-1421.	1.9	19
34	Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 507-516.	1.8	234
35	Abiraterone in Prostate Cancer: A New Angle to an Old Problem. <i>Clinical Cancer Research</i> , 2012, 18, 1848-1854.	3.2	51
36	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	0.6	224
37	RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells. <i>Molecular Endocrinology</i> , 2012, 26, 716-735.	3.7	51

#	ARTICLE	IF	CITATIONS
38	Slug, a Unique Androgen-Regulated Transcription Factor, Coordinates Androgen Receptor to Facilitate Castration Resistance in Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 1496-1507.	3.7	51
39	Overcoming docetaxel resistance in prostate cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 329-340.	1.4	114
40	Oncogenic features of the JMJD2A histone demethylase in breast cancer. <i>International Journal of Oncology</i> , 2012, 41, 1701-1706.	1.4	112
41	In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 1836-1846.	3.7	22
42	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 3457-3462.	0.4	518
43	Antiandrogenic, Maspin Induction, and Antiprostate Cancer Activities of Tanshinone IIA and Its Novel Derivatives with Modification in Ring A. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 971-975.	2.9	42
44	Design, Synthesis, and Biological Evaluation of Nonsteroidal Cycloalkane[d]isoxazole-Containing Androgen Receptor Modulators. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6316-6327.	2.9	30
45	Evidence-based Anticancer Materia Medica for Prostate Cancer. <i>Evidence-based Anticancer Complementary and Alternative Medicine</i> , 2012, , 103-127.	0.1	0
46	Human $\beta$ -tubulin CD133+VE Epithelial Prostate Stem Cells Express Low Levels of Active Androgen Receptor. <i>PLoS ONE</i> , 2012, 7, e48944.	1.1	14
47	Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer. <i>Current Medicinal Chemistry</i> , 2012, 20, 144-157.	1.2	16
48	Stem-Like Cells with Luminal Progenitor Phenotype Survive Castration in Human Prostate Cancer. <i>Stem Cells</i> , 2012, 30, 1076-1086.	1.4	98
49	Therapeutic Options for Advanced Prostate Cancer: 2011 Update. <i>Current Urology Reports</i> , 2012, 13, 170-178.	1.0	13
50	Advances in the management of high-risk localised and metastatic prostate cancer. <i>BJU International</i> , 2012, 109, 8-13.	1.3	11
51	Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. <i>BJU International</i> , 2012, 109, 14-19.	1.3	4
52	Learning From Estrogen Receptor Antagonism: Structure-Based Identification of Novel Antiandrogens Effective Against Multiple Clinically Relevant Androgen Receptor Mutants. <i>Chemical Biology and Drug Design</i> , 2012, 79, 300-312.	1.5	9
53	ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 1-12.	3.3	174
54	Methoxychalcone inhibitors of androgen receptor translocation and function. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2105-2109.	1.0	19
57	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	13.5	257

#	ARTICLE	IF	CITATIONS
58	Adaptation and clonal selection models of castration-resistant prostate cancer: Current perspective. <i>International Journal of Urology</i> , 2013, 20, 362-371.	0.5	40
59	Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 950-956.	2.9	12
60	Prostate Cancer: Shifting from Morphology to Biology. , 2013, , .		1
61	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. <i>Oncogene</i> , 2013, 32, 5501-5511.	2.6	646
62	Sterols are required for cell fate commitment and maintenance of the stomatal lineage in Arabidopsis. <i>Plant Journal</i> , 2013, 74, 1029-1044.	2.8	35
63	Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2013, 30, 1041-1066.	1.3	7
64	Melatonin MT <sub>1</sub> receptor-induced transcriptional up-regulation of p27 <sup>Kip1</sup> in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF- $\kappa$ B): potential implications on prostate cancer chemoprevention and therapy. <i>Journal of Pineal Research</i> , 2013, 54, 69-79.	3.4	54
65	Peptidomimetic targeting of critical androgen receptor coregulator interactions in prostate cancer. <i>Nature Communications</i> , 2013, 4, 1923.	5.8	125
66	Steroidal 5 $\alpha$ -reductase and 17 $\alpha$ -hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 199-222.	1.2	50
67	Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 248-256.	1.2	36
68	Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4880-4898.	2.9	92
69	Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 1-13.	5.0	42
70	The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. <i>Asian Journal of Andrology</i> , 2013, 15, 301-308.	0.8	39
71	Spongian Diterpenoids Inhibit Androgen Receptor Activity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 621-631.	1.9	12
72	Anterior gradient 2 and 3 are two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells. <i>FEBS Journal</i> , 2013, 280, 1249-1266.	2.2	40
73	AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1715-1727.	1.9	73
74	Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3353-3359.	3.2	80
75	Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. <i>International Journal of Oncology</i> , 2013, 42, 35-43.	1.4	51

#	ARTICLE	IF	CITATIONS
76	Looking beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer. <i>Advances in Andrology</i> , 2014, 2014, 1-9.	0.4	1
77	Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer &ndash; role of radium-223. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 373.	0.9	8
78	High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. <i>Cancer Research</i> , 2014, 74, 1272-1283.	0.4	304
79	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. <i>Genome Biology</i> , 2014, 15, 426.	3.8	71
80	Role of miRNA<i>Let-7</i> and Its Major Targets in Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	45
81	Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. <i>Prostate</i> , 2014, 74, 1023-1033.	1.2	22
82	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	5.8	298
83	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
85	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 567-579.	2.7	29
86	Systemic Therapy of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 247-273.	0.1	0
87	Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF- $\kappa$ B. <i>Investigational New Drugs</i> , 2014, 32, 227-234.	1.2	9
88	Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , .	0.1	5
89	Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors. <i>Prostate</i> , 2014, 74, 1400-1410.	1.2	19
90	Steroidogenic Factor 1 Promotes Aggressive Growth of Castration-Resistant Prostate Cancer Cells by Stimulating Steroid Synthesis and Cell Proliferation. <i>Endocrinology</i> , 2014, 155, 358-369.	1.4	23
91	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 555-566.	2.7	45
92	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 153-162.	0.0	0
93	Metformin represses androgenâ€dependent and androgenâ€independent prostate cancers by targeting androgen receptor. <i>Prostate</i> , 2015, 75, 1187-1196.	1.2	51
94	Variant allele of HSD3B1 increases progression to castrationâ€resistant prostate cancer. <i>Prostate</i> , 2015, 75, 777-782.	1.2	23

#	ARTICLE	IF	CITATIONS
95	The Role of Androgen Receptor Expression in the Curative Treatment of Prostate Cancer with Radiotherapy: A Pilot Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	7
96	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	1.2	43
97	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 123-158.	1.9	34
98	Are androgen receptor variants a substitute for the full-length receptor?. <i>Nature Reviews Urology</i> , 2015, 12, 137-144.	1.9	102
99	CYP17A1 inhibitors in castration-resistant prostate cancer. <i>Steroids</i> , 2015, 95, 80-87.	0.8	75
100	Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing. <i>Journal of Clinical Pathology</i> , 2015, 68, 212-217.	1.0	21
101	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	2.9	59
102	Evolutionary Determinants of Cancer. <i>Cancer Discovery</i> , 2015, 5, 806-820.	7.7	350
103	PLC $\mu$ knockdown inhibits prostate cancer cell proliferation via suppression of Notch signalling and nuclear translocation of the androgen receptor. <i>Cancer Letters</i> , 2015, 362, 61-69.	3.2	28
104	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015, 12, 922-936.	2.9	216
105	11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. <i>PLoS ONE</i> , 2016, 11, e0159867.	1.1	113
106	Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2107-2118.	1.9	39
107	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 231-241.	2.0	142
108	Chemotherapy for metastatic castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 726-733.	0.5	14
109	Systems Pharmacology Modeling of Prostate-specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-regulator. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 258-263.	1.3	3
111	Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. <i>Scientific Reports</i> , 2016, 6, 32611.	1.6	97
112	Non-androgen Signaling Pathways in Castration-Resistant Prostate Cancer. , 2016, , 35-63.		1
113	Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 161, 36-44.	1.2	19

#	ARTICLE	IF	CITATIONS
114	Fackel interacts with gibberellic acid signaling and vernalization to mediate flowering in Arabidopsis. <i>Planta</i> , 2017, 245, 939-950.	1.6	12
115	Effect of $N$ -methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2017, 60, 401-409.	0.5	23
116	Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2803-2806.	1.0	23
117	Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 319-333.	1.4	18
118	Rationale for the development of alternative forms of androgen deprivation therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R275-R295.	1.6	17
119	A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids. <i>Molecular and Cellular Endocrinology</i> , 2017, 441, 76-85.	1.6	112
120	mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review. <i>Targeted Oncology</i> , 2017, 12, 47-59.	1.7	59
121	Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer. <i>Prostate</i> , 2017, 77, 60-71.	1.2	13
122	Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study. <i>BMC Genomics</i> , 2017, 18, 526.	1.2	11
123	Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF- $\kappa$ B) Activation and NF- $\kappa$ B Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1130.	1.8	26
124	The histone demethylase $KDM3A$ regulates the transcriptional program of the androgen receptor in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 30328-30343.	0.8	82
126	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2018, 4, 529-539.	1.6	30
127	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 2639-2646.	0.8	131
128	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. <i>Scientific Reports</i> , 2018, 8, 17535.	1.6	23
129	Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 5929-5935.	0.5	4
130	A Membrane Transporter Is Required for Steroid Hormone Uptake in Drosophila. <i>Developmental Cell</i> , 2018, 47, 294-305.e7.	3.1	102
131	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 82.	0.7	68
132	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88



#	ARTICLE	IF	CITATIONS
133	HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain. <i>Molecular Medicine Reports</i> , 2019, 19, 2115-2124.	1.1	2
134	Proteomics contribution to the elucidation of the steroid hormone receptors functions. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 192, 105387.	1.2	3
135	CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines. <i>Current Urology</i> , 2019, 13, 157-165.	0.4	22
136	DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3 $\beta$ and WEE1. <i>Molecular Cell</i> , 2020, 79, 1008-1023.e4.	4.5	32
137	Label-Free Imaging of Cholesterol Assemblies Reveals Hidden Nanomechanics of Breast Cancer Cells. <i>Advanced Science</i> , 2020, 7, 2002643.	5.6	21
138	Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments. <i>Cells</i> , 2020, 9, 2352.	1.8	31
139	Obesity-Related Fatty Acid and Cholesterol Metabolism in Cancer-Associated Host Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 600350.	1.8	8
140	The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2020, 20, 149.	1.8	10
141	Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8006-8017.	1.6	21
142	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
143	From In Silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease. <i>Biomacromolecules</i> , 2020, 21, 1636-1643.	2.6	3
144	Regulation of androgen receptor variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 251-257.	0.5	19
145	Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. <i>Nature Metabolism</i> , 2020, 2, 132-141.	5.1	411
146	Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. <i>Clinical and Translational Medicine</i> , 2021, 11, e495.	1.7	17
147	ROR $\beta$ is a context-specific master regulator of cholesterol biosynthesis and an emerging therapeutic target in cancer and autoimmune diseases. <i>Biochemical Pharmacology</i> , 2022, 196, 114725.	2.0	17
148	Morusflavone, a New Therapeutic Candidate for Prostate Cancer by CYP17A1 Inhibition: Exhibited by Molecular Docking and Dynamics Simulation. <i>Plants</i> , 2021, 10, 1912.	1.6	6
149	The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer. , 2013, , 201-213.		2
150	Androgen Receptor Signaling Interactions Control Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Progression. , 2013, , 227-255.		3

#	ARTICLE	IF	CITATIONS
151	Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. <i>Medical Science Monitor</i> , 2012, 18, CR260-CR264.	0.5	16
152	A Multiscale, Mechanism-Driven, Dynamic Model for the Effects of 5 $\alpha$ -Reductase Inhibition on Prostate Maintenance. <i>PLoS ONE</i> , 2012, 7, e44359.	1.1	4
153	MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 $\beta$ signaling impedes castration-resistant prostate cancer growth. <i>Aging</i> , 2019, 11, 10644-10663.	1.4	8
154	Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer. <i>Aging</i> , 2020, 12, 14699-14717.	1.4	16
155	Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 74724-74733.	0.8	4
156	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. <i>Oncotarget</i> , 2017, 8, 9617-9633.	0.8	18
157	Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16951-16961.	0.8	10
158	Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. <i>Oncotarget</i> , 2015, 6, 22060-22071.	0.8	9
159	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. <i>Oncotarget</i> , 2013, 4, 691-704.	0.8	57
160	Decoding the androgen receptor splice variants. <i>Translational Andrology and Urology</i> , 2013, 2, 178-186.	0.6	115
161	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 580.	0.8	38
162	Molecular signaling involving intrinsically disordered proteins in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 673.	0.8	7
163	Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. <i>Asian Journal of Andrology</i> , 2019, 21, 253.	0.8	17
164	Role of sex hormones in the modulation of cholangiocyte function. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2010, 1, 50.	0.5	20
166	Targeted Therapies and Vaccination. , 2012, , 261-275.		0
167	Arresting Prostate Cancer Growth by Targeting the Androgen Receptor and MAGE-A11. <i>Journal of Steroids &amp; Hormonal Science</i> , 2012, 03, .	0.1	2
168	Androgen Receptor and Steroidogenesis Pathway Control. , 2013, , 79-86.		0
170	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. <i>South Asian Journal of Cancer</i> , 2020, 09, 23-26.	0.2	1

#	ARTICLE	IF	CITATIONS
171	Androgen Signaling in Metastatic Bone Disease. , 2020, , 305-314.		0
172	Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. <i>Current Drug Therapy</i> , 2020, 15, 168-180.	0.2	0
173	Characterisation of human prostate epithelial progenitor differentiation in response to androgens. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, 424-428.	0.3	3
174	Multi-talented DEAD-box proteins and potential tumor promoters: p68 RNA helicase (DDX5) and its paralog, p72 RNA helicase (DDX17). <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 223-34.	0.0	66
175	Abiraterone for the Treatment of Advanced Prostate Cancer. <i>The International Journal of Targeted Therapies in Cancer</i> , 2012, 1, 40-42.	0.0	1
176	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 121-6.	0.4	1
177	Synthesis and preliminary exploration of a NIR fluorescent probe for the evaluation of androgen dependence of prostate cancer. <i>Talanta</i> , 2022, 239, 123058.	2.9	4
178	Rapid Assessment of Insect Steroid Hormone Entry Into Cultured Cells. <i>Frontiers in Physiology</i> , 2021, 12, 816058.	1.3	4
179	The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 787953.	1.3	2
180	Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity. <i>PLoS ONE</i> , 2022, 17, e0258876.	1.1	7
181	Hsa-miR-1290 is associated with stemness and invasiveness in prostate cancer cell lines by targeting RORA. <i>Andrologia</i> , 2022, 54, e14396.	1.0	2
182	Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. <i>ACS Sensors</i> , 2022, 7, 827-838.	4.0	7
183	Insights into Interactions of Human Cytochrome P450 17A1: A Review. <i>Current Drug Metabolism</i> , 2022, 23, 172-187.	0.7	1
184	New Clues to Prognostic Biomarkers of Four Hematological Malignancies. <i>Journal of Cancer</i> , 2022, 13, 2490-2503.	1.2	2
185	Alterations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	4
186	The emerging role of 27-hydroxycholesterol in cancer development and progression: An update. <i>International Immunopharmacology</i> , 2022, 110, 109074.	1.7	17
188	Long non-coding RNA SNHG6 couples cholesterol sensing with mTORC1 activation in hepatocellular carcinoma. <i>Nature Metabolism</i> , 2022, 4, 1022-1040.	5.1	29
189	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12460-12481.	2.9	4

#	ARTICLE	IF	CITATIONS
190	A cryptic transactivation domain of EZH2 binds AR and AR <sup>Δ</sup> splice variant, promoting oncogene activation and tumorous transformation. <i>Nucleic Acids Research</i> , 2022, 50, 10929-10946.	6.5	12
191	Serum cholesterol and the risk of developing hormonally driven cancers: A narrative review. <i>Cancer Medicine</i> , 2023, 12, 6722-6767.	1.3	3
192	Combining Molecular Subtypes with Multivariable Clinical Models has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis. <i>Current Oncology</i> , 2023, 30, 157-170.	0.9	0
193	Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling. <i>Molecular Carcinogenesis</i> , 2023, 62, 940-950.	1.3	2
194	Bacteria in cancer initiation, promotion and progression. <i>Nature Reviews Cancer</i> , 2023, 23, 600-618.	12.8	21
199	Dysregulation of cholesterol metabolism in cancer progression. <i>Oncogene</i> , 2023, 42, 3289-3302.	2.6	2
200	Molekulare Mechanismen der Resistenzentstehung und pathologische Aspekte der Therapieplanung beim Prostatakarzinom. , 2023, , 7-13.		0